Huma Zil E, Sanchez Julie, Lim Herman D, Bridgford Jessica L, Huang Cheng, Parker Bradyn J, Pazhamalil Jiann G, Porebski Benjamin T, Pfleger Kevin D G, Lane J Robert, Canals Meritxell, Stone Martin J
Infection and Immunity Program, Monash Biomedicine Discovery Institute, and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria 3800, Australia.
Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.
Sci Signal. 2017 May 23;10(480):eaai8529. doi: 10.1126/scisignal.aai8529.
Chemokines and their receptors collectively orchestrate the trafficking of leukocytes in normal immune function and inflammatory diseases. Different chemokines can induce distinct responses at the same receptor. In comparison to monocyte chemoattractant protein-1 (MCP-1; also known as CCL2), the chemokines MCP-2 (CCL8) and MCP-3 (CCL7) are partial agonists of their shared receptor CCR2, a key regulator of the trafficking of monocytes and macrophages that contribute to the pathology of atherosclerosis, obesity, and type 2 diabetes. Through experiments with chimeras of MCP-1 and MCP-3, we identified the chemokine amino-terminal region as being the primary determinant of both the binding and signaling selectivity of these two chemokines at CCR2. Analysis of CCR2 mutants showed that the chemokine amino terminus interacts with the major subpocket in the transmembrane helical bundle of CCR2, which is distinct from the interactions of some other chemokines with the minor subpockets of their receptors. These results suggest the major subpocket as a target for the development of small-molecule inhibitors of CCR2.
趋化因子及其受体共同协调白细胞在正常免疫功能和炎症性疾病中的运输。不同的趋化因子可在同一受体上诱导不同的反应。与单核细胞趋化蛋白-1(MCP-1;也称为CCL2)相比,趋化因子MCP-2(CCL8)和MCP-3(CCL7)是其共同受体CCR2的部分激动剂,CCR2是单核细胞和巨噬细胞运输的关键调节因子,而单核细胞和巨噬细胞运输与动脉粥样硬化、肥胖症及2型糖尿病的病理过程相关。通过对MCP-1和MCP-3嵌合体进行实验,我们确定趋化因子的氨基末端区域是这两种趋化因子在CCR2上结合和信号选择性的主要决定因素。对CCR2突变体的分析表明,趋化因子氨基末端与CCR2跨膜螺旋束中的主要亚口袋相互作用,这与其他一些趋化因子与其受体的次要亚口袋的相互作用不同。这些结果表明主要亚口袋可作为开发CCR2小分子抑制剂的靶点。